QuidelOrtho widens FY2024 adjusted diluted EPS range to $1.88-$3.60; midpoint unchanged

QuidelOrtho Corp

Corrected FY2024 adj. diluted EPS guidance: $1.88-$3.60 (midpoint $2.74 unchanged); previously narrower range.
Total revenue guidance unchanged at $2.76-$3.07B; non-respiratory $2.30-$2.34B; respiratory $460-$730M.
Adjusted EBITDA guidance unchanged at $565-$720M (21-24% margin).
Correction filed Feb 16 after initial Feb 13 earnings release and guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.